Dr Topp speaks with ecancer at the 2017 ASH annual meeting about results from the ZUMA-3 trial looking at KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory acute lymphoblastic leukaemia.
He goes on to say that KTE-C19 has shown promising efficacy in adult patients with relapsed/refractory acute lymphoblastic leukaemia.
The safety profile was generally manageable, though Dr Topp highlights the significant impact of PI3K pretreatment on patient outcomes, and additional approaches to improve the risk profile are being explored.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.